spironolactone has been researched along with Obesity in 66 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| " We aimed to identify the biomarker profile and biological meaning of biomarkers associated with obesity to assess the effect of spironolactone on the circulating biomarkers and to explore whether obesity might modify the effect of spironolactone." | 9.51 | The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial. ( Brunner La Rocca, HP; Clark, AL; Cleland, JGF; Cosmi, F; Cuthbert, J; Ferreira, JP; Girerd, N; Hazebroek, MR; Henkens, MHTM; Heymans, SRB; Mariottoni, B; Pellicori, P; Petutschnigg, J; Pizard, A; Rossignol, P; Verdonschot, JAJ; Waring, OJ; Zannad, F, 2022) |
| "This prospective clinical trial was designed to assess the effects of a long-term therapy with spironolactone, with and without dietary-induced weight-loss, on clinical features, lipid profile and insulin levels in women with polycystic ovary syndrome (PCOS)." | 9.11 | Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile. ( Armanini, D; Baro, G; Benedini, S; Mantero, F; Sartorato, P; Scaroni, C; Zulian, E, 2005) |
| "Obesity is common in heart failure with preserved ejection fraction (HFpEF)." | 7.01 | Effect of Obesity on Response to Spironolactone in Patients With Heart Failure With Preserved Ejection Fraction. ( Butler, J; Elkholey, K; Papadimitriou, L; Stavrakis, S; Thadani, U, 2021) |
| "Aldosterone excess has been equally associated with resistant hypertension (RHT) and obstructive sleep apnoea (OSA)." | 6.84 | Effects of continuous positive airway pressure treatment on aldosterone excretion in patients with obstructive sleep apnoea and resistant hypertension: a randomized controlled trial. ( Cavalcanti, AH; Cortez, AF; de Souza, F; Margallo, V; Muxfeldt, ES; Salles, GF, 2017) |
| "Features of visceral obesity and obstructive sleep apnea that may stimulate aldosterone secretion are described here." | 6.44 | Obesity, sleep apnea, aldosterone, and hypertension. ( Goodfriend, TL, 2008) |
| " We aimed to identify the biomarker profile and biological meaning of biomarkers associated with obesity to assess the effect of spironolactone on the circulating biomarkers and to explore whether obesity might modify the effect of spironolactone." | 5.51 | The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial. ( Brunner La Rocca, HP; Clark, AL; Cleland, JGF; Cosmi, F; Cuthbert, J; Ferreira, JP; Girerd, N; Hazebroek, MR; Henkens, MHTM; Heymans, SRB; Mariottoni, B; Pellicori, P; Petutschnigg, J; Pizard, A; Rossignol, P; Verdonschot, JAJ; Waring, OJ; Zannad, F, 2022) |
| "Metabolic syndrome is an important risk factor for proteinuria and chronic kidney disease independent of diabetes and hypertension; however, the underlying mechanisms have not been elucidated." | 5.33 | Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. ( Ando, K; Fujita, T; Gotoda, T; Nagase, M; Nagase, T; Shibata, S; Yoshida, S, 2006) |
| "Our findings demonstrate, for the first time, that blocking MR with chronic, low-dose spironolactone treatment improves paired-associate learning in individuals with obesity, suggesting that MR activation contributes to hippocampal memory modulation in humans." | 5.20 | Effect of mineralocorticoid receptor blockade on hippocampal-dependent memory in adults with obesity. ( Adler, GK; Garg, R; Rotenstein, LS; Sheridan, M, 2015) |
| "We conclude that 6 weeks of treatment with spironolactone does not change insulin sensitivity or endothelial function in normotensive obese individuals with no other comorbidities." | 5.19 | Effect of mineralocorticoid receptor antagonist on insulin resistance and endothelial function in obese subjects. ( Adler, GK; Garg, R; Kneen, L; Williams, GH, 2014) |
| "As myocardial fibrosis might be an important contributor to the association of obesity with left ventricular (LV) dysfunction and heart failure, we investigated the effects of spironolactone on LV function and serological fibrosis markers (procollagen type III N-terminal propeptide (PIIINP) and procollagen type I C-terminal propeptide (PICP)) in patients with obesity and abnormal LV performance." | 5.17 | Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade. ( Kosmala, W; Marwick, TH; Mysiak, A; Przewlocka-Kosmala, M; Szczepanik-Osadnik, H, 2013) |
| "The objective of the study was to use a combination of GR (RU38486, mifepristone) and MR (spironolactone) antagonists to explore the poorly understood activation of the HPA axis that occurs in obesity." | 5.14 | Combined receptor antagonist stimulation of the hypothalamic-pituitary-adrenal axis test identifies impaired negative feedback sensitivity to cortisol in obese men. ( Mattsson, C; Olsson, T; Reynolds, RM; Simonyte, K; Walker, BR, 2009) |
| "The reduction in proteinuria induced by lisinopril (11." | 5.14 | [The antiproteinuric effect of the blockage of the renin-angiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective? ]. ( Gutiérrez Solís, E; Gutiérrez, E; Huerta, A; Morales, E; Praga, M; Segura, J, 2009) |
| "This prospective clinical trial was designed to assess the effects of a long-term therapy with spironolactone, with and without dietary-induced weight-loss, on clinical features, lipid profile and insulin levels in women with polycystic ovary syndrome (PCOS)." | 5.11 | Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile. ( Armanini, D; Baro, G; Benedini, S; Mantero, F; Sartorato, P; Scaroni, C; Zulian, E, 2005) |
| "A fixed, low-dose of spironolactone, added to chronic ACE inhibitor therapy, reduced blood pressure and urinary albumin excretion in obese subjects with hypertension and preexistent target organ damage." | 3.75 | Low-dose spironolactone, added to long-term ACE inhibitor therapy, reduces blood pressure and urinary albumin excretion in obese patients with hypertensive target organ damage. ( Bald, E; Bomback, AS; Chwatko, G; Muskala, P; Nowicki, M, 2009) |
| "The spironolactone Y5 antagonist significantly reduced body weight in C57BL DIO mice, but not in Npy5r(-/-) DIO mice." | 3.74 | Effects of a novel Y5 antagonist in obese mice: combination with food restriction or sibutramine. ( Fukami, T; Gomori, A; Ishihara, A; Ito, J; Iwaasa, H; Kanatani, A; Kitazawa, H; MacNeil, DJ; Mashiko, S; Matsushita, H; Mitobe, Y; Moriya, R; Takahashi, T; Van der Ploeg, LH, 2008) |
| "Obesity is common in heart failure with preserved ejection fraction (HFpEF)." | 3.01 | Effect of Obesity on Response to Spironolactone in Patients With Heart Failure With Preserved Ejection Fraction. ( Butler, J; Elkholey, K; Papadimitriou, L; Stavrakis, S; Thadani, U, 2021) |
| "Aldosterone excess has been equally associated with resistant hypertension (RHT) and obstructive sleep apnoea (OSA)." | 2.84 | Effects of continuous positive airway pressure treatment on aldosterone excretion in patients with obstructive sleep apnoea and resistant hypertension: a randomized controlled trial. ( Cavalcanti, AH; Cortez, AF; de Souza, F; Margallo, V; Muxfeldt, ES; Salles, GF, 2017) |
| "Obesity has been shown to be associated with increased left ventricular mass (LVM) and heart sympathetic activity even in nonhypertensive subjects." | 2.71 | Effect of losartan and spironolactone on left ventricular mass and heart sympathetic activity in prehypertensive obese subjects: a 16-week randomized trial. ( Amador, N; Encarnación, JJ; Guízar, JM; López, M; Rodríguez, L, 2005) |
| "Features of visceral obesity and obstructive sleep apnea that may stimulate aldosterone secretion are described here." | 2.44 | Obesity, sleep apnea, aldosterone, and hypertension. ( Goodfriend, TL, 2008) |
| "Idiopathic hirsutism is the second most common cause." | 2.44 | [Hirsutism]. ( Pijl, H; van Zuuren, EJ, 2007) |
| "Metformin has proven to be effective in the management of the metabolic disturbances, anovulation and hirsutism and is now a widely accepted therapy." | 2.43 | [Polycystic ovary syndrome. New pathophysiological discoveries--therapeutic consequences]. ( Madsbad, S; Nilas, L; Nørgaard, K; Svendsen, PF, 2005) |
| "(Hirsutism is an off-label use of COCs." | 1.72 | Female Pelvic Conditions: Polycystic Ovary Syndrome. ( Brady, PH; Gin, GT; Rosenblum, E; Wilkinson, LD, 2022) |
| "This newly defined subtype of chronic daily headache appears to be caused by a state of elevated CSF pressure." | 1.48 | A New Subtype of Chronic Daily Headache Presenting in Older Women. ( Rozen, TD, 2018) |
| "Metabolic syndrome is a major risk factor for the development of diabetes mellitus and cardiovascular diseases." | 1.42 | Adipocyte Mineralocorticoid Receptor Activation Leads to Metabolic Syndrome and Induction of Prostaglandin D2 Synthase. ( Adler, GK; Alvarez de la Rosa, D; El Mogrhabi, S; Fallo, F; Feraco, A; Jaisser, F; Nguyen Dinh Cat, A; Quilliot, D; Rossignol, P; Sierra-Ramos, C; Touyz, RM; Urbanet, R; Venteclef, N, 2015) |
| "Aldosterone plays a crucial role in cardiovascular disease." | 1.39 | Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity. ( Berger, S; Lohmann, C; Lüscher, TF; Matter, CM; Miranda, MX; Nussberger, J; Ruschitzka, F; Schäfer, N; van Tits, LJ; Vergopoulos, A; Verrey, F; Winnik, S, 2013) |
| "In patients with congestive heart failure (CHF), use of loop diuretic therapy may result in acute kidney insufficiency (AKI)." | 1.39 | Predisposing factors for acute kidney injury in Hispanic patients treated with diuretics for decompensated heart failure. ( Cangiano, JL; López, JE; Marmorato, R; Pagán, P; Ramírez, T; Ricci, F; Soto-Salgado, M; Vega, J, 2013) |
| "Eplerenone treatment significantly reduced insulin resistance, suppressed macrophage infiltration and ROS production in adipose tissues, and corrected the mRNA levels of obesity-related genes in obese mice." | 1.35 | Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. ( Fujita, K; Funahashi, T; Hibuse, T; Hirata, A; Hiuge, A; Kihara, S; Maeda, N; Okada, T; Shimomura, I, 2009) |
| "Metabolic syndrome is an important risk factor for proteinuria and chronic kidney disease independent of diabetes and hypertension; however, the underlying mechanisms have not been elucidated." | 1.33 | Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. ( Ando, K; Fujita, T; Gotoda, T; Nagase, M; Nagase, T; Shibata, S; Yoshida, S, 2006) |
| "Hirsutism is the manifestation of hyperandrogenemia in PCOS." | 1.32 | The treatment of polycystic ovary syndrome. ( Ajossa, S; Guerriero, S; Melis, GB; Orrù, M; Paoletti, AM, 2004) |
| "Total starvation is effective for acute weight reduction in obesity." | 1.26 | [Complications in null-diet]. ( Mordasini, R; Oster, P; Raetzer, H; Schellenberg, B; Schlierf, G, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (18.18) | 18.7374 |
| 1990's | 3 (4.55) | 18.2507 |
| 2000's | 18 (27.27) | 29.6817 |
| 2010's | 25 (37.88) | 24.3611 |
| 2020's | 8 (12.12) | 2.80 |
| Authors | Studies |
|---|---|
| Verdonschot, JAJ | 1 |
| Ferreira, JP | 1 |
| Pizard, A | 1 |
| Pellicori, P | 1 |
| Brunner La Rocca, HP | 1 |
| Clark, AL | 1 |
| Cosmi, F | 1 |
| Cuthbert, J | 1 |
| Girerd, N | 1 |
| Waring, OJ | 1 |
| Henkens, MHTM | 1 |
| Mariottoni, B | 1 |
| Petutschnigg, J | 1 |
| Rossignol, P | 2 |
| Hazebroek, MR | 1 |
| Cleland, JGF | 1 |
| Zannad, F | 1 |
| Heymans, SRB | 1 |
| Bakhtiari, M | 1 |
| Asadipooya, K | 1 |
| Harrington, J | 1 |
| Tseliou, E | 1 |
| Shah, S | 1 |
| Shah, KS | 1 |
| Wilkinson, LD | 1 |
| Brady, PH | 1 |
| Gin, GT | 1 |
| Rosenblum, E | 1 |
| Zeng, X | 1 |
| Xie, YJ | 1 |
| Liu, YT | 1 |
| Long, SL | 1 |
| Mo, ZC | 1 |
| Cadegiani, FA | 1 |
| Goren, A | 1 |
| Wambier, CG | 1 |
| Paulus, R | 1 |
| Schmidt, B | 1 |
| Elkholey, K | 1 |
| Papadimitriou, L | 1 |
| Butler, J | 1 |
| Thadani, U | 1 |
| Stavrakis, S | 1 |
| Rozen, TD | 1 |
| Zhu, JJ | 1 |
| Chen, YP | 1 |
| Yang, M | 1 |
| Liu, BL | 1 |
| Dong, J | 1 |
| Dong, HR | 1 |
| Rui, HL | 1 |
| Cheng, H | 1 |
| Muneyyirci-Delale, O | 1 |
| Co, S | 1 |
| Winer, N | 1 |
| Olatunji, LA | 1 |
| Adeyanju, OA | 1 |
| Michael, OS | 1 |
| Usman, TO | 1 |
| Tostes, RC | 1 |
| Soladoye, AO | 1 |
| Schäfer, N | 1 |
| Lohmann, C | 1 |
| Winnik, S | 1 |
| van Tits, LJ | 1 |
| Miranda, MX | 1 |
| Vergopoulos, A | 1 |
| Ruschitzka, F | 1 |
| Nussberger, J | 1 |
| Berger, S | 1 |
| Lüscher, TF | 1 |
| Verrey, F | 1 |
| Matter, CM | 1 |
| Pojoga, LH | 1 |
| Baudrand, R | 1 |
| Adler, GK | 5 |
| Ricci, F | 1 |
| Ramírez, T | 1 |
| Marmorato, R | 1 |
| Vega, J | 1 |
| Pagán, P | 1 |
| López, JE | 1 |
| Soto-Salgado, M | 1 |
| Cangiano, JL | 1 |
| Hwang, MH | 1 |
| Yoo, JK | 1 |
| Luttrell, M | 1 |
| Kim, HK | 1 |
| Meade, TH | 1 |
| English, M | 1 |
| Segal, MS | 1 |
| Christou, DD | 1 |
| Garg, R | 3 |
| Kneen, L | 1 |
| Williams, GH | 1 |
| Armani, A | 1 |
| Cinti, F | 1 |
| Marzolla, V | 1 |
| Morgan, J | 1 |
| Cranston, GA | 1 |
| Antelmi, A | 1 |
| Carpinelli, G | 1 |
| Canese, R | 1 |
| Pagotto, U | 1 |
| Quarta, C | 1 |
| Malorni, W | 1 |
| Matarrese, P | 1 |
| Marconi, M | 1 |
| Fabbri, A | 1 |
| Rosano, G | 1 |
| Cinti, S | 1 |
| Young, MJ | 1 |
| Caprio, M | 2 |
| Bender, SB | 2 |
| DeMarco, VG | 2 |
| Padilla, J | 1 |
| Jenkins, NT | 1 |
| Habibi, J | 2 |
| Garro, M | 2 |
| Pulakat, L | 1 |
| Aroor, AR | 2 |
| Jaffe, IZ | 1 |
| Sowers, JR | 2 |
| Rotenstein, LS | 1 |
| Sheridan, M | 1 |
| Urbanet, R | 1 |
| Nguyen Dinh Cat, A | 1 |
| Feraco, A | 1 |
| Venteclef, N | 1 |
| El Mogrhabi, S | 1 |
| Sierra-Ramos, C | 1 |
| Alvarez de la Rosa, D | 1 |
| Quilliot, D | 1 |
| Fallo, F | 1 |
| Touyz, RM | 1 |
| Jaisser, F | 1 |
| Jia, G | 1 |
| Ramirez-Perez, FI | 1 |
| Martinez-Lemus, LA | 1 |
| Hayden, MR | 1 |
| Sun, Z | 1 |
| Meininger, GA | 1 |
| Manrique, C | 1 |
| Whaley-Connell, A | 1 |
| Takahashi, F | 1 |
| Goto, M | 1 |
| Wada, Y | 1 |
| Hasebe, N | 1 |
| de Souza, F | 1 |
| Muxfeldt, ES | 1 |
| Margallo, V | 1 |
| Cortez, AF | 1 |
| Cavalcanti, AH | 1 |
| Salles, GF | 1 |
| Goodfriend, TL | 1 |
| Mattsson, C | 1 |
| Reynolds, RM | 1 |
| Simonyte, K | 1 |
| Olsson, T | 1 |
| Walker, BR | 1 |
| Hirata, A | 2 |
| Maeda, N | 2 |
| Hiuge, A | 1 |
| Hibuse, T | 1 |
| Fujita, K | 1 |
| Okada, T | 2 |
| Kihara, S | 1 |
| Funahashi, T | 2 |
| Shimomura, I | 2 |
| Morales, E | 1 |
| Huerta, A | 1 |
| Gutiérrez, E | 1 |
| Gutiérrez Solís, E | 1 |
| Segura, J | 1 |
| Praga, M | 1 |
| Bomback, AS | 1 |
| Muskala, P | 1 |
| Bald, E | 1 |
| Chwatko, G | 1 |
| Nowicki, M | 1 |
| Artini, PG | 1 |
| Di Berardino, OM | 1 |
| Simi, G | 1 |
| Papini, F | 1 |
| Ruggiero, M | 1 |
| Monteleone, P | 1 |
| Cela, V | 1 |
| Tirosh, A | 1 |
| Costa, MB | 1 |
| Andrade Ezequiel, DG | 1 |
| Morais Lovis, JC | 1 |
| Oliveira, MM | 1 |
| Baumgratz de Paula, R | 1 |
| Polyzos, SA | 1 |
| Kountouras, J | 1 |
| Zavos, C | 1 |
| Deretzi, G | 1 |
| Tokuyama, H | 1 |
| Wakino, S | 1 |
| Hara, Y | 1 |
| Washida, N | 1 |
| Fujimura, K | 1 |
| Hosoya, K | 1 |
| Yoshioka, K | 1 |
| Hasegawa, K | 1 |
| Minakuchi, H | 1 |
| Homma, K | 1 |
| Hayashi, K | 1 |
| Itoh, H | 1 |
| Nakatsuji, H | 1 |
| Hiuge-Shimizu, A | 1 |
| Billings, FT | 1 |
| Pretorius, M | 1 |
| Schildcrout, JS | 1 |
| Mercaldo, ND | 1 |
| Byrne, JG | 1 |
| Ikizler, TA | 1 |
| Brown, NJ | 1 |
| Bendersky, M | 1 |
| Kosmala, W | 1 |
| Przewlocka-Kosmala, M | 1 |
| Szczepanik-Osadnik, H | 1 |
| Mysiak, A | 1 |
| Marwick, TH | 1 |
| BLOCH, J | 1 |
| de Paula, RB | 1 |
| da Silva, AA | 1 |
| Hall, JE | 1 |
| Ajossa, S | 1 |
| Guerriero, S | 1 |
| Paoletti, AM | 1 |
| Orrù, M | 1 |
| Melis, GB | 1 |
| Amador, N | 1 |
| Encarnación, JJ | 1 |
| Guízar, JM | 1 |
| Rodríguez, L | 1 |
| López, M | 1 |
| Zulian, E | 1 |
| Sartorato, P | 1 |
| Benedini, S | 1 |
| Baro, G | 1 |
| Armanini, D | 1 |
| Mantero, F | 1 |
| Scaroni, C | 1 |
| Svendsen, PF | 1 |
| Nilas, L | 1 |
| Nørgaard, K | 1 |
| Madsbad, S | 1 |
| Fleischman, A | 1 |
| Mansfield, J | 1 |
| Nagase, M | 2 |
| Yoshida, S | 1 |
| Shibata, S | 2 |
| Nagase, T | 1 |
| Gotoda, T | 2 |
| Ando, K | 1 |
| Fujita, T | 2 |
| Tubek, S | 1 |
| Fève, B | 1 |
| Claës, A | 1 |
| Viengchareun, S | 1 |
| Lombès, M | 1 |
| Zennaro, MC | 1 |
| Pimenta, E | 1 |
| Calhoun, DA | 1 |
| Oparil, S | 1 |
| Matsui, H | 1 |
| van Zuuren, EJ | 1 |
| Pijl, H | 1 |
| Mashiko, S | 1 |
| Ishihara, A | 1 |
| Iwaasa, H | 1 |
| Moriya, R | 1 |
| Kitazawa, H | 1 |
| Mitobe, Y | 1 |
| Ito, J | 1 |
| Gomori, A | 1 |
| Matsushita, H | 1 |
| Takahashi, T | 1 |
| MacNeil, DJ | 1 |
| Van der Ploeg, LH | 1 |
| Fukami, T | 1 |
| Kanatani, A | 1 |
| Aron, DC | 1 |
| Tyrrell, JB | 1 |
| Fitzgerald, PA | 1 |
| Findling, JW | 1 |
| Forsham, PH | 1 |
| Zhurova, MV | 1 |
| Rybina, LV | 1 |
| Mendonca, E | 1 |
| Albuquerque, L | 1 |
| Jacome, L | 1 |
| Luis, ML | 1 |
| Rosa, FC | 1 |
| Lovejoy, JC | 1 |
| Bray, GA | 1 |
| Bourgeois, MO | 1 |
| Macchiavelli, R | 1 |
| Rood, JC | 1 |
| Greeson, C | 1 |
| Partington, C | 1 |
| Spark, RF | 2 |
| Arky, RA | 2 |
| Boulter, PR | 2 |
| Saudek, CD | 1 |
| O'Brian, JT | 1 |
| Oster, P | 1 |
| Mordasini, R | 1 |
| Raetzer, H | 1 |
| Schellenberg, B | 1 |
| Schlierf, G | 1 |
| Kolanowski, J | 1 |
| Desmecht, P | 1 |
| Crabbé, J | 1 |
| McKenna, KM | 1 |
| Pepperell, RJ | 1 |
| Evans, J | 1 |
| Giocoli, G | 1 |
| Casanova, P | 1 |
| Delboy, C | 1 |
| Bittnerová, H | 1 |
| Rath, R | 1 |
| Masek, J | 1 |
| Plauchu, M | 1 |
| Bourlier, V | 1 |
| Meunier, P | 1 |
| Mugler, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "Bioprofiling Response to Mineralocorticoid Receptor Antagonists for the Prevention of Heart Failure. A Proof of Concept Clinical Trial Within the EU FP 7 (European Union FP7) HOMAGE Programme Heart OMics in AGing "[NCT02556450] | Phase 2 | 528 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| Effectiveness of the Combination Liraglutide and Metformin on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With Polycystic Ovarian Syndrome, Obesity and Infertility[NCT05952882] | Phase 3 | 188 participants (Anticipated) | Interventional | 2023-11-01 | Not yet recruiting | ||
| Mineralocorticoid Receptor and Obesity Induced Cardiovascular Complications[NCT01406015] | 38 participants (Actual) | Interventional | 2009-02-28 | Completed | |||
| HYpertension Therapy With Valsartan Versus EpleRenone for Obese Patients: A Randomized Clinical Trial[NCT03476616] | Phase 4 | 330 participants (Anticipated) | Interventional | 2018-09-01 | Not yet recruiting | ||
| Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension[NCT05593055] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-08-25 | Recruiting | ||
| Efficacy of Continuous Positive Airway Pressure (CPAP) on Blood Pressure Control of Resistant Hypertension Patients With Obstructive Sleep Apnea Syndrome (OSAS).[NCT01508754] | Phase 4 | 125 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| Cardiometabolic Effects of Eplerenone in HIV Infection[NCT02629094] | Phase 2 | 5 participants (Actual) | Interventional | 2015-12-02 | Terminated | ||
| The Effect of Spironolactone and Vitamin E Versus Vitamin E on Serum Adipocytokines Levels in Patients With Biopsy-proven Nonalcoholic Fatty Liver Disease-A Phase II Study[NCT01147523] | Phase 2 | 30 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| RAAS, Inflammation, and Post-operative AF[NCT00141778] | Phase 2/Phase 3 | 455 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| Pilot Randomized Controlled Trial of Spironolactone in Young Women With Nonalcoholic Steatohepatitis (NASH)[NCT03576755] | Phase 1/Phase 2 | 20 participants (Actual) | Interventional | 2019-01-09 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Insulin resistance was measured using the 75 G glucose tolerance test. Participants ingested 75 grams of glucose in 300-400 mL of water over 5 minutes. Blood samples were taken before ingesting glucose and then every 30 minutes for 120 minutes. HOMA-IR was calculated using the Insulin and glucose levels obtained. A negative change (decrease in insulin resistance) indicates improvement. (NCT01406015)
Timeframe: Baseline and Week 6 (Prior to ingesting glucose and every 30 minutes for 120 minutes)
| Intervention | IR index (Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Week 6 | |
| Placebo | 3.4 | 0.1 |
| Spironolactone | 2.7 | 0.1 |
Insulin sensitivity was measured using the 75 gram (G) glucose tolerance test. Participants ingested 75 grams of glucose in 300-400 milliliters (mL) of water over 5 minutes. Blood samples were taken before ingesting glucose and then every 30 minutes for 120 minutes. Insulin sensitivity index was calculated by Matsuda and Defronzo's formula using the values obtained. A positive change from Baseline (increase in insulin sensitivity) indicates improvement. (NCT01406015)
Timeframe: Baseline and Week 6 (Prior to ingesting glucose and every 30 minutes for 120 minutes)
| Intervention | IS index (Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Week 6 | |
| Placebo | 4.6 | -1.1 |
| Spironolactone | 3.7 | -0.1 |
Renal plasma blood flow was determined by clearance of para-aminohippurate (PAH). A loading dose of PAH (8 mg/kg) was given intravenously followed by a 1 hour constant infusion of PAH at a rate of 12 mg/minute (min). Plasma samples were obtained at Baseline and at 50 and 60 minutes. PAH clearance was calculated from the plasma levels and infusion rates and reported in millimeters (mL)/minute (min). A positive change from Baseline indicates improvement. (NCT01406015)
Timeframe: Baseline and Week 6 (Prior to PAH infusion and at 50 and 60 minutes post PAH infusion)
| Intervention | mL/min (Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Week 6 | |
| Placebo | 521 | -5.2 |
| Spironolactone | 488 | -2.3 |
Ultrasonography of the brachial artery was performed to evaluate endothelial function by flow mediated dilatation (FMD) studies. A blood pressure cuff was placed on the participant's upper arm and was compressed for 5 minutes. After release of compression, brachial artery diameter and blood flow velocity were measured. FMD was expressed as the percentage change in brachial artery diameter. A positive change from Baseline indicates improvement. (NCT01406015)
Timeframe: Baseline and Week 6
| Intervention | percent dilalation (Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Week 6 | |
| Placebo | 10.2 | -2.0 |
| Spironolactone | 9.6 | -1.2 |
Mean change in intraventricular septum percentage of lipid by MR spectroscopy. This was calculated by subtracting the baseline intraventicular septum percentage value of lipid from the week 24 intraventicular septum percentage value of lipid by MR spectroscopy. (NCT02629094)
Timeframe: 24 weeks
| Intervention | percentage of lipid (Mean) |
|---|---|
| Eplerenone | -0.33 |
Mean change in hepatic percentage of lipid by MR spectroscopy. This was calculated by subtracting the baseline hepatic percentage value of lipid from the week 24 hepatic percentage value of lipid by MR spectroscopy. (NCT02629094)
Timeframe: 24 weeks
| Intervention | percentage of lipid (Mean) |
|---|---|
| Eplerenone | 13 |
Percentage of patients with a creatinine concentrations >2.5mg/dl (NCT00141778)
Timeframe: Measured until the time of hospital discharge, from 5.7 to 6.8 days on average, depending on the study group.
| Intervention | percentage of patients (Number) |
|---|---|
| Placebo | 5.4 |
| Ramipril | 0.7 |
| Spironolactone | 0.7 |
The percentage of patients in each study arm who died. (NCT00141778)
Timeframe: Measured until the time of hospital discharge
| Intervention | percentage of patients (Number) |
|---|---|
| Placebo | 1.4 |
| Ramipril | 2.0 |
| Spironolactone | 0 |
Percentage of patients who had a serum potassium concentrations <3.5 milliequivalents (mEq)/L (NCT00141778)
Timeframe: Measured until the time of hospital discharge, which was an average of 5.7 to 6.8 days depending on the treatment arm.
| Intervention | percentage of patients (Number) |
|---|---|
| Placebo | 11.6 |
| Ramipril | 13.8 |
| Spironolactone | 6.8 |
Percentage of patients with hypotension defined as a systolic blood pressure <90 mmHg and/or prolonged requirement for vasopressor use. (NCT00141778)
Timeframe: Measured during and after surgery, until discharge, from 5.7 to 6.8 days on average.
| Intervention | percentage of patients (Number) |
|---|---|
| Placebo | 5.4 |
| Ramipril | 10.6 |
| Spironolactone | 10.2 |
(NCT00141778)
Timeframe: Measured from the day of surgery until the time of hospital discharge
| Intervention | days (Mean) |
|---|---|
| Placebo | 6.8 |
| Ramipril | 5.7 |
| Spironolactone | 5.8 |
The primary endpoint of the study was the percentage of patients with electrocardiographically confirmed AF of at least 10 secs duration at any time following the end of surgery until hospital discharge, an average from 5.7 days in the ramipril group to 6.8 days in the placebo group. Patients were monitored continuously on telemetry throughout the postoperative period until discharge. Electrocardiograms were obtained for any rhythm changes detected on telemetry monitoring, and in addition, electrocardiograms were performed preoperatively, at admission to the intensive care unit, and daily starting on postoperative day 1. All electrocardiograms and rhythm strips were reviewed in a blinded fashion by a single cardiac electrophysiologist. (NCT00141778)
Timeframe: Measured from admission to the ICU until discharge from hospital
| Intervention | percentage of patients (Number) |
|---|---|
| Placebo | 27.2 |
| Ramipril | 27.8 |
| Spironolactone | 25.9 |
Percentage of patients in each study group who experience a cerebrovascular event, confirmed by CT. (NCT00141778)
Timeframe: Measured until the time of hospital discharge, from 5.7 to 6.8 days on average depending on the study arm.
| Intervention | percentage of patients (Number) |
|---|---|
| Placebo | 2.7 |
| Ramipril | 1.3 |
| Spironolactone | 2.0 |
It is the time in minutes that it took to extubate the patient after surgery. (NCT00141778)
Timeframe: It is the time (in minutes) from admission to the ICU until tracheal extubation
| Intervention | minutes (Mean) |
|---|---|
| Placebo | 1091.3 |
| Ramipril | 970.1 |
| Spironolactone | 576.4 |
C-reactive protein was measured at several time points (see table) over the course of the study. (NCT00141778)
Timeframe: Perioperative period
| Intervention | ug/mL (Mean) | ||||
|---|---|---|---|---|---|
| Initiation of surgery | Postoperative day 1 | Postoperative day 2 | Postoperative day 3 | Postoperative day 4 | |
| Placebo | 4.1 | 51.4 | 134.8 | 128.3 | 94.1 |
| Ramipril | 4.3 | 49.9 | 131.0 | 164.8 | 105.2 |
| Spironolactone | 3.9 | 64.3 | 127.8 | 189.4 | 126.5 |
Interleukin-6 was measured at several time points (see time points in table) over the course of the study (NCT00141778)
Timeframe: Perioperative period
| Intervention | pg/ml (Mean) | |||||
|---|---|---|---|---|---|---|
| Initiation of surgery | 30min intraop | 60min intraop | Postop | Postoperative day 1 | Postoperative day 2 | |
| Placebo | 4.7 | 12.0 | 15.6 | 130.0 | 119.0 | 100.3 |
| Ramipril | 4.6 | 20.5 | 28.8 | 202.1 | 171.0 | 95.5 |
| Spironolactone | 6.6 | 11.3 | 17.4 | 145.7 | 164.9 | 109.6 |
Plasminogen activator inhibitor-1 (PAI-1) was measured at several time points (see table) over the course of the study. (NCT00141778)
Timeframe: Perioperative period
| Intervention | ng/mL (Mean) | |||||
|---|---|---|---|---|---|---|
| Initiation of surgery | 30min intraop | 60min intraop | Postop | Postoperative day 1 | Postoperative day 2 | |
| Placebo | 19.6 | 19.2 | 21.0 | 36.4 | 55.2 | 28.1 |
| Ramipril | 16.2 | 19.7 | 22.0 | 38.9 | 47.9 | 25.7 |
| Spironolactone | 17.3 | 17.3 | 20.1 | 34.0 | 48.9 | 31.0 |
9 reviews available for spironolactone and Obesity
| Article | Year |
|---|---|
Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity.
Topics: Androgens; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin Resistance; Metformin; Obe | 2020 |
Obesity, sleep apnea, aldosterone, and hypertension.
Topics: Aldosterone; Humans; Hypertension; Metabolic Syndrome; Mineralocorticoid Receptor Antagonists; Obesi | 2008 |
Best methods for identification and treatment of PCOS.
Topics: Androgens; Aromatase Inhibitors; Clomiphene; Contraceptives, Oral, Hormonal; Diagnosis, Differential | 2010 |
Mineralocorticoid receptor antagonists and the metabolic syndrome.
Topics: Aldosterone; Antihypertensive Agents; Eplerenone; Humans; Hypertension; Inflammation; Insulin Resist | 2010 |
[Resistant hypertension].
Topics: Age Factors; Aldosterone; Coronary Vasospasm; Disease Management; Diuretics; Humans; Hyperaldosteron | 2012 |
[Polycystic ovary syndrome. New pathophysiological discoveries--therapeutic consequences].
Topics: Contraceptives, Oral; Diabetes Mellitus, Type 2; Female; Genetic Predisposition to Disease; Humans; | 2005 |
Mechanisms and treatment of resistant hypertension.
Topics: Blood Pressure Monitoring, Ambulatory; Contraceptives, Oral; Diuretics; Drug Resistance; Humans; Hyp | 2007 |
[Hirsutism].
Topics: Androgen Antagonists; Androgens; Contraceptives, Oral; Cyproterone Acetate; Female; Hirsutism; Human | 2007 |
Renin, aldosterone and glucagon in the natriuresis of fasting.
Topics: Adrenocorticotropic Hormone; Aldosterone; Dietary Carbohydrates; Dietary Proteins; Fasting; Fludroco | 1975 |
15 trials available for spironolactone and Obesity
| Article | Year |
|---|---|
The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial.
Topics: Biomarkers; Female; Glucose Intolerance; Heart Failure; Humans; Male; Mineralocorticoid Receptor Ant | 2022 |
Effect of Obesity on Response to Spironolactone in Patients With Heart Failure With Preserved Ejection Fraction.
Topics: Aged; Comorbidity; Diuretics; Double-Blind Method; Female; Heart Failure; Humans; Male; Obesity; Pre | 2021 |
Mineralocorticoid receptors modulate vascular endothelial function in human obesity.
Topics: Abdominal Fat; Aged; Body Composition; Body Mass Index; Brachial Artery; Cross-Over Studies; Double- | 2013 |
Effect of mineralocorticoid receptor antagonist on insulin resistance and endothelial function in obese subjects.
Topics: Adolescent; Adult; Aldosterone; Blood Pressure; Body Mass Index; Body Weight; Brachial Artery; Doubl | 2014 |
Effect of mineralocorticoid receptor antagonist on insulin resistance and endothelial function in obese subjects.
Topics: Adolescent; Adult; Aldosterone; Blood Pressure; Body Mass Index; Body Weight; Brachial Artery; Doubl | 2014 |
Effect of mineralocorticoid receptor antagonist on insulin resistance and endothelial function in obese subjects.
Topics: Adolescent; Adult; Aldosterone; Blood Pressure; Body Mass Index; Body Weight; Brachial Artery; Doubl | 2014 |
Effect of mineralocorticoid receptor antagonist on insulin resistance and endothelial function in obese subjects.
Topics: Adolescent; Adult; Aldosterone; Blood Pressure; Body Mass Index; Body Weight; Brachial Artery; Doubl | 2014 |
Effect of mineralocorticoid receptor blockade on hippocampal-dependent memory in adults with obesity.
Topics: Adult; Animals; Female; Hippocampus; Humans; Magnetic Resonance Imaging; Male; Memory; Middle Aged; | 2015 |
Effects of continuous positive airway pressure treatment on aldosterone excretion in patients with obstructive sleep apnoea and resistant hypertension: a randomized controlled trial.
Topics: Aged; Aldosterone; Continuous Positive Airway Pressure; Coronary Vasospasm; Diuretics; Female; Follo | 2017 |
Combined receptor antagonist stimulation of the hypothalamic-pituitary-adrenal axis test identifies impaired negative feedback sensitivity to cortisol in obese men.
Topics: Adult; Blood Pressure; Cross-Over Studies; Double-Blind Method; Feedback; Female; Hormone Antagonist | 2009 |
[The antiproteinuric effect of the blockage of the renin-angiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective? ].
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benz | 2009 |
Aldosterone antagonist decreases blood pressure and improves metabolic parameters in obese patients with the metabolic syndrome.
Topics: Adult; Aged; Blood Pressure; Female; Humans; Hypertension; Male; Metabolic Syndrome; Middle Aged; Mi | 2010 |
Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade.
Topics: Body Mass Index; Double-Blind Method; Echocardiography, Doppler; Female; Fibrosis; Follow-Up Studies | 2013 |
Effect of losartan and spironolactone on left ventricular mass and heart sympathetic activity in prehypertensive obese subjects: a 16-week randomized trial.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Body Mass Index; Diuretics; Double-Blind Method; Ech | 2005 |
Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile.
Topics: Adolescent; Adult; Androgen Antagonists; Area Under Curve; Body Mass Index; Caloric Restriction; Die | 2005 |
Exogenous androgens influence body composition and regional body fat distribution in obese postmenopausal women--a clinical research center study.
Topics: Adipose Tissue; Androgen Antagonists; Androgens; Body Composition; Cardiovascular Diseases; Female; | 1996 |
Sodium balance and renal tubular sensitivity to aldosterone during total fast and carbohydrate refeeding in the obese.
Topics: Aldosterone; Fasting; Female; Glucose; Humans; Kidney Tubules; Natriuresis; Obesity; Spironolactone; | 1976 |
[Clinical test of a diuretic preparation combining a spironoloctone and a sulfonamide derivative].
Topics: Adult; Aged; Clinical Trials as Topic; Diuretics; Female; Heart Failure; Humans; Male; Middle Aged; | 1965 |
42 other studies available for spironolactone and Obesity
| Article | Year |
|---|---|
Metainflammation in COVID-19.
Topics: Aged; Angiotensin-Converting Enzyme 2; COVID-19; Dipeptidyl Peptidase 4; Eplerenone; Female; Humans; | 2022 |
Paying Homage to the Power of Proteomics: Insights Into Obesity and Heart Failure From the HOMAGE Trial.
Topics: Heart Failure; History, 20th Century; Humans; Obesity; Proteomics; Spironolactone | 2022 |
Female Pelvic Conditions: Polycystic Ovary Syndrome.
Topics: Acne Vulgaris; Anovulation; Female; Finasteride; Gonadotropin-Releasing Hormone; Hirsutism; Humans; | 2022 |
Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS).
Topics: Androgen Antagonists; Androgens; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhi | 2020 |
90-year-old man • dyspnea • lower extremity edema • limitations in daily activities • Dx?
Topics: Activities of Daily Living; Aged, 80 and over; Diagnosis, Differential; Diuretics; Dyspnea; Edema; F | 2020 |
A New Subtype of Chronic Daily Headache Presenting in Older Women.
Topics: Acetazolamide; Cerebrospinal Fluid Pressure; Female; Head-Down Tilt; Headache Disorders; Humans; Mid | 2018 |
Aldosterone is involved in the pathogenesis of obesity-related glomerulopathy through activation of Wnt/β-catenin signaling in podocytes.
Topics: Aldosterone; Animals; beta Catenin; Disease Models, Animal; Down-Regulation; Eplerenone; Glomerulone | 2018 |
Vascular compliance in women with polycystic ovary syndrome treated with spironolactone.
Topics: Adult; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Elasticity; Female; Glucose Intoler | 2018 |
Ameliorative effect of low-dose spironolactone on obesity and insulin resistance is through replenishment of estrogen in ovariectomized rats.
Topics: Animals; Dose-Response Relationship, Drug; Estrogens; Female; Inflammation Mediators; Insulin Resist | 2019 |
Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity.
Topics: Adipose Tissue; Aldosterone; Animals; Antioxidants; Aorta; Cyclooxygenase 1; Cyclooxygenase Inhibito | 2013 |
Mineralocorticoid receptor throughout the vessel: a key to vascular dysfunction in obesity.
Topics: Animals; Diet, High-Fat; Endothelium, Vascular; Eplerenone; Male; Mineralocorticoid Receptor Antagon | 2013 |
Predisposing factors for acute kidney injury in Hispanic patients treated with diuretics for decompensated heart failure.
Topics: Acute Kidney Injury; Adult; Aged; Blood Urea Nitrogen; Creatinine; Diabetes Mellitus; Drug Utilizati | 2013 |
Mineralocorticoid receptor antagonism induces browning of white adipose tissue through impairment of autophagy and prevents adipocyte dysfunction in high-fat-diet-fed mice.
Topics: Adipocytes; Adipogenesis; Adipose Tissue, Brown; Adipose Tissue, White; Aldosterone; Androstenes; An | 2014 |
Mineralocorticoid receptor antagonism treats obesity-associated cardiac diastolic dysfunction.
Topics: Animals; Diastole; Disease Models, Animal; Echocardiography; Heart Ventricles; Mineralocorticoid Rec | 2015 |
Adipocyte Mineralocorticoid Receptor Activation Leads to Metabolic Syndrome and Induction of Prostaglandin D2 Synthase.
Topics: 3T3-L1 Cells; Adipocytes, White; Aldosterone; Animals; Cell Line, Tumor; Dibenzocycloheptenes; Enzym | 2015 |
Low-Dose Mineralocorticoid Receptor Blockade Prevents Western Diet-Induced Arterial Stiffening in Female Mice.
Topics: Animals; Aorta; Arteriosclerosis; Diet, Western; Dose-Response Relationship, Drug; Endothelial Cells | 2015 |
Successful Treatment with an Antihypertensive Drug Regimen Including Eplerenone in a Patient with Malignant Phase Hypertension with Renal Failure.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cal | 2015 |
Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice.
Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue; Animals; Eplerenone; Insulin Resistance; Male; Mice; Mice, | 2009 |
Low-dose spironolactone, added to long-term ACE inhibitor therapy, reduces blood pressure and urinary albumin excretion in obese patients with hypertensive target organ damage.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Blood Pressure Monitoring, Am | 2009 |
Spironolactone revisited.
Topics: Blood Pressure; Female; Humans; Hypertension; Male; Metabolic Syndrome; Mineralocorticoid Receptor A | 2011 |
Role of mineralocorticoid receptor/Rho/Rho-kinase pathway in obesity-related renal injury.
Topics: Animals; Chemokine CCL2; Diet, Fat-Restricted; Diet, High-Fat; Eplerenone; Gene Expression Regulatio | 2012 |
Contribution of glucocorticoid-mineralocorticoid receptor pathway on the obesity-related adipocyte dysfunction.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; 3T3-L1 Cells; Adipocytes; Adipokines; Animals; Body Mas | 2012 |
Obesity and oxidative stress predict AKI after cardiac surgery.
Topics: Acute Kidney Injury; Aged; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Body Mass Index; Ca | 2012 |
[Cushing's syndrome, adiposity, hyperaldosteronism. Effect of spirolactone].
Topics: Adiposity; Cushing Syndrome; Humans; Hyperaldosteronism; Obesity; Spironolactone | 1963 |
Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration.
Topics: Animals; Dogs; Eplerenone; Glomerular Filtration Rate; Hemodynamics; Hormones; Hypertension; Mineral | 2004 |
The treatment of polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Cabergoline; Cardiovascular Diseases; Clomiphene; Cyproterone Acetate; | 2004 |
Diagnosis and treatment of polycystic ovarian syndrome and insulin resistance.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Hyperandrogenism; Hyperlipidemia | 2005 |
Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors.
Topics: Adipocytes; Adrenal Glands; Aldosterone; Animals; Cyclic N-Oxides; Disease Models, Animal; Eplerenon | 2006 |
Differences in selected zinc metabolism parameters in obese and normal-weight hypertensive patients following treatment with spironolactone.
Topics: Adolescent; Adult; Body Mass Index; Case-Control Studies; Humans; Hypertension; Middle Aged; Mineral | 2006 |
Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis.
Topics: Adipocytes, White; Adipogenesis; Adipose Tissue, White; Aldosterone; Animals; Cell Differentiation; | 2007 |
Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress.
Topics: Aldosterone; Animals; Antioxidants; Cyclic N-Oxides; Disease Models, Animal; Eplerenone; Hypertensio | 2007 |
Effects of a novel Y5 antagonist in obese mice: combination with food restriction or sibutramine.
Topics: Adiposity; Animals; Anti-Obesity Agents; Appetite Depressants; Blood Glucose; Body Weight; Caloric R | 2008 |
Cushing's syndrome: problems in diagnosis.
Topics: ACTH Syndrome, Ectopic; Adenoma; Adrenal Cortex Function Tests; Adrenocortical Hyperfunction; Adult; | 1981 |
[Effect of verospiron and hypothiazide on the indices of electrolyte metabolism in neuroendocrinological obesity].
Topics: Adolescent; Adult; Diuretics; Female; Humans; Hydrochlorothiazide; Middle Aged; Mineralocorticoid Re | 1980 |
Pseudotumor cerebri in a patient with Bartter's syndrome and obesity.
Topics: Adolescent; Bartter Syndrome; Female; Hematologic Tests; Humans; Indomethacin; Obesity; Potassium Ch | 1996 |
[Complications in null-diet].
Topics: Acetone; Adult; Allopurinol; Arrhythmias, Cardiac; Diet, Reducing; Edema; Female; Humans; Ischemic A | 1977 |
Hirsutism in a gynaecological context.
Topics: Adult; Anovulation; Contraceptives, Oral, Hormonal; Female; Gonadal Steroid Hormones; Hirsutism; Hum | 1990 |
Effect of aldosterone blockade during fasting and refeeding.
Topics: Adrenal Glands; Adult; Aldosterone; Dietary Carbohydrates; Fasting; Female; Humans; Kidney Tubules, | 1973 |
[Sodium balance during fasting and realimentation with special reference to a form of therapy for obesity].
Topics: Aldosterone; Diet, Sodium-Restricted; Fasting; Food; Glucose Tolerance Test; Humans; Insulin; Ketone | 1971 |
[On the pathogenesis of the changes in water, sodium, and potassium metabolism caused by fasting in obese women].
Topics: Aldosterone; Diet; Fasting; Female; Humans; Obesity; Potassium; Sodium; Spironolactone; Water-Electr | 1969 |
[Spironolactone-benzothiadiazine association in the treatment of female obesity with water and salt retention].
Topics: Adult; Aged; Benzothiadiazines; Female; Humans; Middle Aged; Obesity; Spironolactone | 1965 |
[Effects of spirolactone in some cases of obesity (study of 53 cases)].
Topics: 17-Ketosteroids; Adrenal Cortex Hormones; Adult; Aldosterone; Female; Humans; Middle Aged; Obesity; | 1965 |